share_log

Pharma Company Organicell Partners With Beauty Health Focusing On Aging & Inflammation Signs

Pharma Company Organicell Partners With Beauty Health Focusing On Aging & Inflammation Signs

製藥公司Organicell與Beauty Health合作，專注於衰老和炎症跡象
Benzinga Real-time News ·  2022/09/16 11:16
  • Biopharmaceutical company Organicell Regenerative Medicine Inc (OTC:OCEL) plans to expand into the skincare and haircare industries in partnership with Beauty Health Co (NASDAQ:SKIN).
  • BeautyHealth's Hydrafacial, with Organicell, will create the first to-market exosome booster for their patented Hydrafacial device.
  • Hydrafacial's new exosome booster will be available early next year.
  • Organicell is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics and regenerative medicine.
  • Organicell's science team will work with Hydrafacial to prove the efficacy of how this new booster application may reduce inflammation, increase collagen, and increase elastin.
  • "This partnership is the first of many we are working on in the aesthetic and hair space," said Organicell's CEO, Matt Sinnreich.
  • Last week, Organicell secured an additional $11 million in financing in preparation for clinical trial enrollment.
  • Organicell has been approved by the FDA to conduct Phase I/II clinical trials on their investigational new drug, Zofin.
  • Price Action: OCEL shares are trading higher by 4.13% at $0.05 on the last check Friday.
  • 生物製藥公司Organicell再生醫學公司(場外交易代碼：OCEL)計劃與以下公司合作進軍護膚和護髮行業美容保健公司(納斯達克：皮膚)。
  • BeautyHealth的HydraFacial將與Organicell合作，為他們的專利HydraFacial設備創造第一個上市的外體助推器。
  • HydraFacal的新Exosome助推器將於明年初上市。
  • Organicell是一家臨牀階段的生物製藥公司，專注於開發創新的生物療法和再生醫學。
  • Organicell的科學團隊將與HydraFacial合作，證明這種新的助推劑應用程序如何減少炎症、增加膠原蛋白和增加彈性蛋白的有效性。
  • Organicell首席執行官馬特·辛瑞奇表示：“這是我們在美容和頭髮領域開展的眾多合作中的第一個。”
  • 上週，Organicell獲得了另外1100萬美元的融資，為臨牀試驗登記做準備。
  • Organicell已經獲得FDA的批准，可以對他們的研究新藥Zofin進行I/II期臨牀試驗.
  • 價格行動：在週五的最後一次檢查中，OCEL的股價上漲了4.13%，達到0.05美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論